Media Hub

Jan 2017

Life-extending breast cancer drug set to be withdrawn from NHS

The life-extending drug, Kadcyla, has been rejected by NICE for NHS use in England, believing that the price is too expensive. In clinical trials, Kadcyla, which costs an average of £90,000 per patient, was found to extend terminal breast cancer patients’ lives by around six months, and also dramatically improves the patient’s quality of life…

Read More